Growth hormone treatment in Prader-Willi syndrome patients: systematic review and meta-analysis.

ABSTRACT:

Background

Growth hormone (GH) treatment is currently recommended in Prader-Willi syndrome (PWS) patients.

Objectives

To evaluate the impact (efficacy and safety) of the use of recombinant human GH (rhGH) as a treatment for PWS.

Method

We performed a systematic review and, where possible, meta-analysis for the following outcomes: growth, body mass index, body composition, cognitive function, quality of life, head circumference, motor development/strength, behaviour and adverse effects. We included all PWS patients, with all types of genetic defects and with or without GH deficiency, who participated in rhGH studies performed in infancy, childhood and adolescence, that were either randomised controlled trials (RCTs) (double-blinded or not) or non-randomised controlled

SUBMITTER: Passone CGB 

PROVIDER: S-EPMC7213882 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature